Story: The EU must allow the prices of medicines to rise to the American levels to attract investments.
Those were the messages from the bosses of two European pharmaceutical giants Wednesday (April 23).
Novartis CEO VAS Narasimhan and Sanofi leader Paul Hudson wrote in the financial age of Great -Britain that European price checks and austerity measures reduce the attractiveness of its markets.
They further said that competitiveness in European biopharma is decreasing, and the uncertainty of rates is harming stimuli to invest in the EU.
They believe that the block should determine higher catalog prices and have called for communication about spending goals for new medicines to reward innovation.
They also want the EU to strengthen its domestic market.
And warned his pharmaceutical model of production in Europe and exporting to the US cannot continue.
In recent weeks, drug makers have promised to invest in the US to tackle rates.
Washington says that the goal is to stimulate domestic production.
Roche said on Tuesday that it would invest $ 50 billion in the US in the next five years.
Novartis, Eli Lilly and Johnson & Johnson recently also announced significant investments.
In the meantime, the Trump government has warned drug makers that it is considering linking US medicine prices to lower amounts paid by other developed countries.
The US pays the most for drugs in the world, often almost three times that of other developed countries.
